References
- Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006;66:8762–9.
- Hui KF, Chiang AK. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. Int J Cancer. 2010;126:2479–89.
- Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78:1893–902.
- Iwata S, Saito T, Ito Y, Kamakura M, Gotoh K, Kawada J, et al.. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer Sci. 2011;103(2):375–81.
- Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al.. Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood. 2011;117:6297–303.
- Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, et al.. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106:235–40.
- Kieff E, Rickinson A. Epstein-Barr virus and its replication. In: , Fields B, Knipe D, Howley P M, ed, editors. Fields virology. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 2603–55.
- Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology. 2006;346:385–93.
- Hong M, Murai Y, Kutsuna T, Takahashi H, Nomoto K, Cheng CM, et al.. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol. 2006;132:1–8.
- Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, et al.. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009;5:e1000341.
- Guasparri I, Bubman D, Cesarman E. EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood. 2008;111:3813–20.
- Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med. 2004;199:993–1003.
- Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene. 2011;30:1379–89.
- Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A. 2006;103:720–5.
- DiNardo CD, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol. 2010;17:368–74.
- Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C, et al.. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010;5:e10126.